Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 241–300 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
… were reviewed, mainly meropenem (39.7%), ertapenem (21.2%) and linezolid (6.2%). Most treatments were empirical (52.4%) or targeted (42.…
…rometry (Q Exactive Plus instrumentation) were used to quantify metformin concentrations. Values below 100 ng/ml were deemed subtherapeut…
…roup (88.6% vs 63%).SR related complications were higher in the midazolam group: agitation (50% vs 47,8%), delirium (25% vs 4,3%), hypote…
…ted patient, the off-label addition of DA-EPOCH chemotherapy to mogamulizumab provided enhanced clinical benefit compared with prior monother…
…ase describes severe immune-mediated toxicity after one dose of ipilimumab (1 mg/kg) and nivolumab (3 mg/kg) in a stage IV patient who dev…
…tick bites and red meat ingestion. His home medication included simvastatin, omeprazole, bromazepam and an emergency epinephrine autoinject…
…s conducted including NDMM patients aged ≥80 years treated with daratumumab from its introduction until January 2025. Baseline variables in…
… kidney disease progression by 24% [HR 0.76; 95% CI 0.67–0.87]. Canagliflozin reduced the composite renal outcome [HR 0.66; 95% CI 0.53–0.81]…
…etabolizers is not affected by an upfront 30% dose reduction of irinotecan. Therefore, UGT1A1 genotype-guided dosing of irinotecan can be …
…e need for metabolite monitoring and vigilance when prescribing AZA in SLE pregnancies.…
… points; 95% confidence interval [CI], 12.5 to 33.6; P<0.0001). Obinutuzumab was superior to placebo with statistically significant benefit …
…ths after rituximabConclusions In patients with thrombotic APS, rituximab treatment may prevent thrombotic recurrence with a significant …